|
| CLAGM with doseescalated mitoxantrone for adults with acute myeloid leukemia |
|
https://doi.org/10.18632/oncotarget.26383
Anna B. Halpern, and Roland B. Walter
|
| 36543-36544 |
|
| Cancer immunotherapy: Moving beyond checkpoint inhibition |
|
https://doi.org/10.18632/oncotarget.26384
Marianne Boes
|
| 36545-36546 |
|
| Genomic biomarker of checkpoint efficacy highways for precision medicine in lung cancer |
|
https://doi.org/10.18632/oncotarget.26389
Francois Ghiringhelli, and Caroline Truntzer
|
| 36547-36548 |
|
| Using genomics to better define highrisk MGUS/SMM patients |
|
https://doi.org/10.18632/oncotarget.26390
Ankit K. Dutta, Duncan R. Hewett, J. Lynn Fink, and Andrew C.W. Zannettino
|
| 36549-36550 |
|
| IGFBP2 is a potential biomarker in acute kidney injury AKI and resveratrolloaded nanoparticles prevent AKI |
|
https://doi.org/10.18632/oncotarget.25663
Hai-Lun Li, Zhuan Yan, Zun-Ping Ke, Xiao-Feng Tian, Li-Li Zhong, Yong-Tao Lin, Yong Xu, and Dong-Hui Zheng
|
| 36551-36560 |
|
| Significance of intranuclear angiotensinII type 2 receptor in oral squamous cell carcinoma |
|
https://doi.org/10.18632/oncotarget.26337
Sayako Matsushima-Otsuka, Rina Fujiwara-Tani, Takamitsu Sasaki, Hitoshi Ohmori, Chie Nakashima, Shingo Kishi, Yukiko Nishiguchi, Kiyomu Fujii, Yi Luo, and Hiroki Kuniyasu
|
| 36561-36574 |
|
| Preoperative diffusionweighted magnetic resonance imaging and intraoperative frozen sections for predicting the tumor grade in endometrioid endometrial cancer |
|
https://doi.org/10.18632/oncotarget.26366
Tomohito Tanaka, Yoshito Terai, Satoe Fujiwara, Yoshimichi Tanaka, Hiroshi Sasaki, Satoshi Tsunetoh, Kazuhiro Yamamoto, Takashi Yamada, Yoshifumi Narumi, and Masahide Ohmichi
|
| 36575-36584 |
|
| Cotreatment of tumor cells with hyaluronan plus doxorubicin affects endothelial cell behavior independently of VEGF expression |
|
https://doi.org/10.18632/oncotarget.26379
Daiana L. Vitale, Fiorella M. Spinelli, Daiana Del Dago, Antonella Icardi, Gianina Demarchi, Ilaria Caon, Mariana GarcÃa, Marcela F. Bolontrade, Alberto Passi, Carolina Cristina, and Laura Alaniz
|
| 36585-36602 |
|
| Clofarabine/busulfanbased reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGMTC |
|
https://doi.org/10.18632/oncotarget.26391
Amandine Le Bourgeois, Myriam Labopin, Mathieu Leclerc, Régis Peffault de Latour, Jean-Henri Bourhis, Patrice Ceballos, Corentin Orvain, Hélène Labussière Wallet, Karin Bilger, Didier Blaise, Marie-Thérese Rubio, Thierry Guillaume, Mohamad Mohty, Patrice Chevallier, and on behalf of Société Francophone de Greffe de Moelle et de Thérapie Cellulaire
|
| 36603-36612 |
|
| Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia |
|
https://doi.org/10.18632/oncotarget.26400
Nikhil Patkar, Rohan Kodgule, Chinmayee Kakirde, Goutham Raval, Prasanna Bhanshe, Swapnali Joshi, Shruti Chaudhary, Y. Badrinath, Sitaram Ghoghale, Shraddha Kadechkar, Syed Hasan Khizer, Sadhana Kannan, Dhanalaxmi Shetty, Anant Gokarn, Sachin Punatkar, Hasmukh Jain, Bhausaheb Bagal, Hari Menon, Manju Sengar, Navin Khattry, Prashant Tembhare, Papagudi Subramanian, and Sumeet Gujral
|
| 36613-36624 |
|
| Metaanalysis of the likelihood of FOXC1 expression in early and latestage tumors |
|
https://doi.org/10.18632/oncotarget.26358
Tsutomu Kume, and Tarek Shackour
|
| 36625-36630 |
|
| Tumour treating fields in a combinational therapeutic approach |
|
https://doi.org/10.18632/oncotarget.26344
Joshua Branter, Surajit Basu, and Stuart Smith
|
| 36631-36644 |
|
| Correction: The antirheumatic drug leflunomide synergizes with MEK inhibition to suppress melanoma growth |
|
https://doi.org/10.18632/oncotarget.26415
Kimberley Hanson, Stephen D. Robinson, Karamallah Al-Yousuf, Adam E. Hendry, Darren W. Sexton, Victoria Sherwood, and Grant N. Wheeler
|
| 36645-36645 |
